Sector Experts

Subscribe to
Streetwise Reports

Ask this Expert

Companies Commented On

  • Acceleron Pharma Inc.
  • Anthera Pharmaceuticals Inc.
  • Ardelyx, Inc.
  • Argos Therapeutics Inc.
  • BIND Therapeutics Inc.
  • Bristol-Myers Squibb Co.
  • Cardinal Health Inc.
  • Celgene Corp.
  • Celldex Therapeutics Inc.
  • Cerulean Pharma Inc.
  • Cerus Corp.
  • Compugen Ltd.
  • Concert Pharmaceuticals
  • CytoSorbents Corp.
  • Gilead Sciences Inc.
  • Incyte Corp.
  • Infinity Pharmaceuticals Inc.
  • KaloBios Pharmaceuticals Inc.
  • Karyopharm Therapeutics Inc.
  • Loxo Oncology Inc
  • Merck & Co. Inc.
  • Navidea Biopharmaceuticals Inc.
  • Novartis AG
  • Novavax Inc.
  • OncoGenex Pharmaceuticals Inc.
  • OncoMed Pharmaceuticals Inc.
  • OvaScience
  • Pharmacyclics Inc.
  • Roche Holding AG
  • Synta Pharmaceuticals Corp.
  • TG Therapeutics Inc.
  • Verastem Inc.
  • Vitae Pharmaceuticals Inc.

Michael G. King, Jr.

JMP Securities

Image: Michael G. King, Jr.

Michael G. King Jr. is a managing director and senior biotechnology analyst at JMP Securities. King comes to JMP from Rodman & Renshaw LLC, where he was managing director and senior biotechnology analyst. He has more than 17 years of experience as a leading biotechnology equity research analyst, consistently ranking at the top of Institutional Investor magazine's annual sellside research survey, in addition to being named that publication's "Home Run Hitter" in 2000. King also served as senior vice president of corporate development and communication at ZIOPHARM Oncology (ZIOP:NASDAQ). Prior to joining ZIOPHARM, King was a managing director and senior biotechnology analyst at Wedbush Securities. He holds a bachelor's degree in finance from Baruch College.




Recent Interviews

Exuberant, Yes: Michael King on How the Oncology Drug Development Machine Builds Biotech Wealth (3/13/14) Veteran biotechnology analyst Michael King of JMP Securities has seen drug development evolve from hit-or-miss to the sophisticated, high-throughput discovery techniques in place today. He understands the sector, the entrepreneurs and the valuations as well as anyone on Wall Street. In this interview with The Life Sciences Report, King zeros in on the oncology space, his focus for nearly two decades. Never single-minded, King's stable of thoroughbred names includes a bonus pick he likes very much in the field of fertility.

Biotech Watchlist 2014: Sound Science, Innovative Ideas and a Sprinkle of Pixie Dust (1/15/14) stethbillfold82142013 was a banner year for the life sciences sector, with biotech, pharmaceutical and medtech companies buoyed by advances in therapeutic techniques, a friendly regulatory environment, lucrative partnerships and the overall market upswing. The 2013 Biotech Watchlist, which was released at the Biotech Showcase in San Francisco, reflected this robustness, boasting a year-to-date return that blew past those posted by the major indices. Credit the basket of stocks picked by industry experts, weighted heavily with winners. Can our panel of experts pick another winning portfolio in 2014? Find out which companies they've chosen for the 2014 Watchlist in this exclusive from The Life Sciences Report and Sagient Research.

Scientific Conferences Create Buzz and Move Biotech Stocks: Michael King (9/5/13) It's that time again. From Labor Day through the New Year, analysts jet off to conferences across the U.S. and Europe to hear data they've been waiting on for years. Michael King, managing director and senior biotechnology analyst at JMP Securities, has been at this game for almost two decades, and he has a firm grip on how data releases about molecules and their targets will affect the biotech stocks in his coverage. In this interview with The Life Sciences Report, King also names four growth companies making important advances in hematologic cancers. Just in time.

Recent Quotes

"ASTX's shares still sell well below where we believe they could trade." (9/16/13) Astex Pharmaceuticals Inc. - Michael G. King, Jr., JMP Securities More >

"We are reiterating our Market Outperform rating on ASTX." (8/19/13) Astex Pharmaceuticals Inc. - Michael G. King, Jr., JMP Securities More >

"We maintain our Market Outperform rating on CYCC." (8/14/13) Cyclacel Pharmaceuticals Inc. - Michael G. King, Jr., JMP Securities More >

"We maintain our Market Outperform rating on CYCC." (8/14/13) Cyclacel Pharmaceuticals Inc. - Michael G. King, Jr., JMP Securities More >

"We continue to view ASTX as a highly attractive mid-cap play in the biotech space." (8/1/13) Astex Pharmaceuticals Inc. - Michael G. King, Jr., JMP Securities More >

"We maintain our Outperform rating for ASTX." (7/8/13) Astex Pharmaceuticals Inc. - Michael G. King, Jr., JMP Securities More >

"We are initiating coverage on CYCC with a Market Outperform rating." (7/2/13) Cyclacel Pharmaceuticals Inc. - Michael G. King, Jr., JMP Securities More >

"We reiterate our Market Outperform rating on ASTX." (4/30/13) Astex Pharmaceuticals Inc. - Michael G. King, Jr., JMP Securities More >



Due to permission requirements, not all quotes are shown.